Opal Biosciences

Strategic Acquisition and Capital Raise: offering 10,000,000 shares at $0.25 each to raise $2.5 million: prerequisite for the share-based acquisition of Formulytica Pty Ltd, a growing revenue-generating business based in Melbourne, enhancing Opal’s capabilities and market reach.

Government Support: $5 million grant by the WA government to establish a pharmaceutical manufacturing facility in Perth, further solidifying its market position.

Innovative Focus: The new facility will produce sterile liquid pharmaceutical products suitable for personalized medicine, such as patient-specific cancer vaccines, and clinical trial supplies. This addresses a growing need in the Australian pharmaceutical market.

Intellectual Property and Expertise: grow its in-house intellectual property portfolio. Formulytica brings specialized expertise in pharmaceutical development, creating a valuable platform for the merged entity.

Diverse Clientele and Strong Shareholder Base: international/local companies and medical research groups. 

Experienced Leadership: The board and management team have significant experience in capital raising, acquisitions, and exits, ensuring that the company is well-positioned to execute its growth plans effectively.

Global Market Opportunity: The company aims to meet the significantly increased requirement for onshore manufacturing in Australia, driven by growth in clinical trials and the evolving market for personalized medicines. This positions Opal to capture a substantial market share both locally and internationally.

These investment highlights make Opal Biosciences an attractive opportunity for investors looking for growth and innovation in the pharmaceutical sector.

---

Opal BioSciences Information Memorandum

Opal capital raise for growth strategy | IM Announcement

---